An overnight increase in CO2 predicts mortality in sleep disordered breathing

BACKGROUND AND OBJECTIVE

Sleep disordered breathing (SDB) is highly prevalent but under-recognized. Evidence is accumulating for its role as a predictor of mortality independent of cardiovascular risk factors. The role of hypercapnia in SDB is not known systematically, and between 11 and 43% of patients with SDB develop chronic hypercapnia. Hypercapnia predicts mortality in other respiratory conditions. The role of hypercapnia in independently predicting mortality in patients with SDB after assessing for the presence of airways disease and obesity was investigated.

METHODS

The records of 396 consecutive patients were examined retrospectively. Univariate and multivariate analyses were performed using Cox proportional hazards regression to determine the association between gas exchange and polysomnography (PSG) variables and all-cause mortality, adjusted for potential confounders, including age, gender and presence of co-morbidity and airways disease.

RESULTS

The mean age of our patient population was 55 ± 15 years, and the mean body mass index (BMI) was 30.6 ± 6.2 kg/m2 . Out of the 322 patient population, 258 were men. After 10 years, 25% had died, following a maximum follow-up of 16.7 years. Mortality among patients with SDB was predicted by a difference between evening and morning PaCO2 (ΔPaCO2 ) of ≥7 mm Hg and evening hypoxaemia (PaO2 < 65 mm Hg), independent of age and the presence of co-morbidity and airways disease. There was a significant correlation between minimum oxygen saturation (SpO2 ) and ΔPaCO2  ≥ 7 mm Hg (P = 0.002) and evening PaO2 < 65 mm Hg (P < 0.001).

CONCLUSIONS

An overnight increase in CO2 and evening hypoxaemia are independent mortality predictors in SDB. A low minimum SpO2 identifies patients in whom morning and evening arterial blood gases are beneficial.

Diagnostic dilemmas in pulmonary hypertension

Dilemmas persist in the screening, assessment, and follow-up of patients with pulmonary hypertension, relating to issues of whom and how to screen, how to resolve ambiguities in the clinical classification of patients with multiple potential substrates of pulmonary vascular disease, how to interpret test results, how to integrate multiple clinical parameters into a global diagnosis, how to use ambiguous test results, how to determine disease severity and prognosis, and how to monitor patients on treatment. This article describes how to incorporate available information into the diagnostic process, and where lack of concrete data should impose caution in patient management.

Força muscular respiratória de mulheres obesas mórbidas e eutróficas

A obesidade mórbida é uma condição clínica que afeta a capacidade funcional, sendo a musculatura respiratória igualmente comprometida. Objetivou-se avaliar a força muscular inspiratória e expiratória de mulheres obesas mórbidas (MO) e eutróficas (ME). Estudo transversal com amostra composta por 21 mulheres (14 MO e 7 ME), pareadas pela idade e altura. A avaliação da força muscular inspiratória e expiratória foi realizada por meio da verificação das pressões inspiratória e expiratória por manovacuometria. Quando comparadas as pressões respiratórias estáticas máximas obtidas com os valores preditos para ME e MO, constata-se que as do primeiro grupo apresentam valores de P Imáx=119,14±1,9 cmH2O (152% do predito) e P Emáx=141,1±10,2 cmH2O (98,5% do predito) dentro dos limites de normalidade ou acima, enquanto no grupo de obesas mórbidas os valores de P Imáx=66±18,7 cmH2O (84,3% do predito) e P Emáx=78,4±14,2 cmH2O (54,3% do predito) foram inferiores aos preditos. Comparando-se as pressões respiratórias estáticas máximas obtidas de MO com ME, observa-se diferença significativa tanto para os valores de P Imáx (66±18,7 versus 119±1,9 cmH2O) como P Emáx (78,4±14,2 versus 141,14±10,20) com significância estatística de 0,001. Conclui-se que a força muscular respiratória é marcadamente diminuída em MO, quando comparadas a ME.

Obesity hypoventilation syndrome: mechanisms and management

Obesity hypoventilation syndrome describes the association between obesity and the development of chronic daytime alveolar hypoventilation. This syndrome arises from a complex interaction between sleep-disordered breathing, diminished respiratory drive, and obesity-related respiratory impairment, and is associated with significant morbidity and mortality. Therapy directed toward reversing these abnormalities leads to improved daytime breathing, with available treatment options including positive pressure therapy, weight loss, and pharmacological management. However, a lack of large-scale, well-designed studies evaluating these various therapies has limited the development of evidence-based treatment recommendations. Although treatment directed toward improving sleep-disordered breathing is usually effective, not all patients tolerate mask ventilation and awake hypercapnia may persist despite effective use. In the longer term, weight loss is desirable, but data on the success and sustainability of this approach in obesity hypoventilation are lacking. The review outlines the major mechanisms believed to underlie the development of hypoventilation in this subgroup of obese patients, their clinical presentation, and current therapy options.